Search
IN01
go.drugbank.com/drugs/DB16434ExperimentalOf note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … The IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria[L30543].
Levoketoconazole
go.drugbank.com/drugs/DB05667ApprovedStill, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole]. … changes in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections.
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. … Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014.
Categories: Topoisomerase II InhibitorsPentaerythritol tetranitrate
go.drugbank.com/drugs/DB06154ApprovedWithdrawnIt is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395]. … It is a pentaerythritol nitrate in which all four hydroxy groups of pentaerythritol have been converted to the corresponding nitrate ester.
Categories: Vasodilators Used in Cardiac DiseasesProducts: Peritrate Sa 80mg TabCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined. … [L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.
Categories: Compounds used in a research, industrial, or household settingCrotamiton
go.drugbank.com/drugs/DB00265ApprovedCrotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. … It is miscible with alcohol and with methanol.
Categories: Compounds used in a research, industrial, or household settingProducts: A-Bite Cream, CROTAMITON LOCION AL 10 %Daprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigational[A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin … [A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia.
Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]
Favezelimab
go.drugbank.com/drugs/DB16729InvestigationalFavezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022] … [A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated.
Products: Dabigatranetexilat 1A Pharma 75 mg - Hartkapseln, Dabigatranetexilat 1A Pharma 110 mg - Hartkapseln